A promising new treatment for Alzheimer's disease?
O'Brien
John T
JT
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D003866:Depressive Disorder / Q000139:chemically induced; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000037:antagonists & inhibitors / Q000378:metabolism; D015990:Placebo Effect; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000378:metabolism; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007211:Indoles; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; C010119:latrepirdine